Combined targeted modality in cHL: a risky bet?

Authors

Bastian von Tresckow (ORCID: https://orcid.org/0000-0003-1410-4487)
Paul J. Bröckelmann (ORCID: https://orcid.org/0000-0001-9662-9900)

Institutions

University of Cologne (DE)
Essen University Hospital (DE)
University Hospital Cologne (DE)
Max Planck Institute for Biology of Ageing (DE)
University of Duisburg-Essen (DE)

Publication Details

Journal: Blood
Published: 2025-01-16
DOI: https://doi.org/10.1182/blood.2024027360
Primary Topic: Lymphoma Diagnosis and Treatment
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Combined targeted modality in cHL: a risky bet?

Bastian von Tresckow, Paul J. Bröckelmann

Jan 16, 2025

Blood

Lymphoma Diagnosis and Treatment

article

Combined targeted modality in cHL: a risky bet?

Bastian von Tresckow, Paul J. Bröckelmann

January 16, 2025article en

Abstract

No abstract available for this paper.

BloodVol. 145(3)

University of Cologne (DE), Essen University Hospital (DE), University Hospital Cologne (DE), Max Planck Institute for Biology of Ageing (DE), University of Duisburg-Essen (DE)

Openalex Percentile: Top 99%

Lymphoma Diagnosis and Treatment

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Combined targeted modality in cHL: a risky bet? — Bastian von Tresckow, Paul J. Bröckelmann · Blood (2025) | TGRS Research Map | TGRS